Scrip Pharma Law: Paving the US biosimilars pathway
This article was originally published in Scrip
Executive Summary
As part of Barack Obama's landmark healthcare reform, the US has created a statutory pathway for the approval of biosimilars. We examine four key issues facing the FDA and how the experience of other medicines regulators may be instructive.